Novadaq price target raised to $26 from $23 at Canaccord Canaccord raised its price target on Novadaq calling it the most compelling growth story in med-tech because it possesses one of the largest TAM opportunities in their group. The firm expects the company to re-acquire US marketing rights for SPY Elite in 2015 and then go direct thereafter resulting in higher average selling prices. Shares are Buy rated.
News For NVDQ From The Last 14 Days
Check below for free stories on NVDQ the last two weeks.